
The competition to develop the next blockbuster weight loss drug is heating up, and Pfizer is looking to make a big splash with its own entry.
On Tuesday, Pfizer presented the latest trial data on its ultra-long-acting GLP-1 experimental drug, code-named PF’3944. People taking PF’3944 lost significantly more weight than those on a placebo, the trial showed, even after switching to a monthly schedule. The company will push forward several Phase III trials of the drug this year.

![[CITYPNG.COM]White Google Play PlayStore Logo – 1500×1500](https://startupnews.fyi/wp-content/uploads/2025/08/CITYPNG.COMWhite-Google-Play-PlayStore-Logo-1500x1500-1-630x630.png)